Bio Saga Blog - A Chronicle of Life Sciences & Informatics

• Expands specialty diagnostics portfolio with attractive molecular diagnostics capabilities, including infectious disease testing • Complements leading life sciences offering with innovative sample preparation, assay and bioinformatics technologies  • Creates significant value and is expected to be immediately accretive to adjusted earnings per share after close WALTHAM, Mass. and VENLO, The Netherlands – March 3, 2020 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to the closing price of QIAGEN’s common stock on the Frankfurt Prime Standard on Ma...

Nuclea Biotechnologies and Thermo Fisher Scientific said today that they are collaborating on multiplexed mass spec assays for quantifying native insulin and its therapeutic analogs. Nuclea plans to use the assays to analyze patient samples as part of the company's diabetes research collaborations. The assays will be developed at Thermo Fisher's Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center and will be run using Thermo Fisher's MSIA immunoenrichment technology and its TSQ Vantage or Quantiva mass spec instruments. "We’ve already worked with the BRIMS Center to develop two other very important assays," Nuclea CEO Patrick Muraca said in a statement. "These assays have demonstrated the sensitivity, precision, and robustness needed for high-throughput detection of clinically relevant isoforms of target proteins." "The real-world application of multiplexed MS-based methods to type 2 diabetes presents an opportunity to advance ...